openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Intersect ENT Inc (NASDAQ: XENT)

04-18-2020 02:43 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Intersect ENT Inc (NASDAQ: XENT) shares.

An investigation on behalf of current long term investors in Intersect ENT Inc (NASDAQ: XENT) shares.

An investigation on behalf of current long-term investors in shares of Intersect ENT Inc (NASDAQ: XENT) concerning potential breaches of fiduciary duties by certain directors and officers of Intersect ENT Inc (NASDAQ: XENT was announced.

Investors who are current long term investors in Intersect ENT Inc (NASDAQ: XENT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in (NASDAQ: XENT stocks follows a lawsuit filed against Intersect ENT Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: XENT stocks, concerns whether certain Intersect ENT directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that the Defendants failed to disclose to investors that the Company lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, that, as a result, the Company's sales force would focus on ensuring reimbursement, that, as a result, the Company's sales representatives were less focused on driving sales, that physicians were less likely to adopt the Company's SINUVA due to transaction costs associated with seeking reimbursement, that the Company would increase staffing to address these issues, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Intersect ENT Inc (NASDAQ: XENT) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Intersect ENT Inc (NASDAQ: XENT) here

News-ID: 2015650 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for ENT

10-30-2025 | Health & Medicine
Getnews
Consultant ENT Surgeon Sri Mahalingam Now Practicing at Tunbridge ENT in London
Sri Mahalingam at Tunbridge-ENT is a leading consultant ENT Surgeon providing private ear, nose, and throat care in Harley Street, London. The practice serves patients dealing with persistent ENT conditions that affect their daily comfort, sleep quality, and overall wellbeing. Many people struggle for months with recurring sinus problems, hearing difficulties, or throat issues before finding the right specialist care they need. Sri Mahalingam offers comprehensive assessment and treatment for adults
Surge In Prevalence Of Ent Disorders Sparks Growth In Ent Devices Market Driver: …
What Are the Projected Growth and Market Size Trends for the ENT Devices Market? The market for ENT devices has been experiencing robust growth in the past few years. It is projected to expand from $33.82 billion in 2024 to $37.04 billion in 2025, marking a compound annual growth rate (CAGR) of 9.5%. The growth seen during the historical period can be linked to an aging population, chronic conditions, healthcare reimbursements,
Surge In Prevalence Of Ent Disorders Sparks Growth In Ent Devices Market Driver: …
"What Are the Projected Growth and Market Size Trends for the ENT Devices Market? The market for ENT devices has been experiencing robust growth in the past few years. It is projected to expand from $33.82 billion in 2024 to $37.04 billion in 2025, marking a compound annual growth rate (CAGR) of 9.5%. The growth seen during the historical period can be linked to an aging population, chronic conditions, healthcare reimbursements,
ENT Surgical Devices And Equipment Market Report 2024 - ENT Devices Market Insig …
"The Business Research Company recently released a comprehensive report on the Global ENT Surgical Devices And Equipment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your
ENT Diagnostic Devices Market Facts, Figures and Analytical Insights, 2018 to 20 …
ENT diagnostic devices market is estimated to hit US$ 2.3 billion in 2019, according to a new study by Fact.MR. The market grew at 6.3% y-o-y in 2018 with bronchoscopes accounting for nearly one third of the global revenues. Overall growth of the ENT diagnostic devices market can be attributed to, Advanced technology incorporations in ENT diagnostic devices Favorable reimbursement policies for ENT procedures Development of efficient and low-priced devices According to Fact.MR study,
ENT Workstation Market Segmentation By product type Fixed ENT Workstation, Porta …
The diagnosis and treatment of diseases occurring in upper air passages and ENT organs require thorough attention. The growing need for the usage of qualitative modern equipment to perform ENT procedures as well as the need for improved accessibility of doctor’s instruments to inspect a large patient pool plays a fundamental role in driving the demand for ENT workstations in the market. The usage of ENT workstations in ENT clinics